Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded ...

In a report released on March 31, Andrew Berens from Leerink Partners maintained a Hold rating on IDEAYA Biosciences (IDYA – Research Report).

Trump has repeatedly called April 2 “Liberation Day,” alluding to a more sweeping and aggressive set of tariffs. Leerink ...

AirSculpt Technologies (NASDAQ:AIRS – Get Free Report) had its price target decreased by equities research analysts at Leerink Partners from $6.50 to $2.50 in a research note issued to investors on ...

Leerink Partners analyst Puneet Souda maintained a Hold rating on Hologic (HOLX – Research Report) on March 28. The company’s shares opened ...

Leerink Partnrs lowered shares of Equillium (NASDAQ:EQ – Free Report) from a strong-buy rating to a hold rating in a research report released on Friday,Zacks.com reports. Leerink Partnrs also issued ...

(“Innate” or the “Company”) today announced that members of its executive team will present and host 1x1 meetings at the Leerink Partners 2025 Global Healthcare Conference being held on ...

SAN DIEGO, March 4, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ...

Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Leerink Partners Global Healthcare Conference in Miami, Florida. Dr. Brady’s ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...